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EpigeneticsDuring the processes leading to adverse cardiac remodeling andheart failure, cardiomyocytes react to neurohumoral
stimuli and biomechanical stress by activating pathways that induce pathological hypertrophy. The gene
expression patterns andmolecular changes observed during cardiac hypertrophic remodeling bare resemblance
to those observed during fetal cardiac development. The re-activation of fetal genes in the adult failing heart is a
complex biological process that involves transcriptional, posttranscriptional and epigenetic regulation of the
cardiac genome. In this review, the mechanistic actions of transcription factors, microRNAs and chromatin
remodeling processes in regulating fetal gene expression in heart failure are discussed.
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Heart failure is a serious clinical disorder that represents the primary
cause of hospitalization and death in Europe and in the United States. In
numerous types of heart diseases including ischemic diseases, hyper-
tension, aortic stenosis, valvular dysfunctions and genetic forms of
cardiomyopathies, hypertrophic remodeling is a common observable
process. Sustained pathological hypertrophy still represents the major
clinical predictor of heart failure and sudden cardiac death in humans
[1,2].
At the cellular level, pathological hypertrophy can be largely
regarded as the response of cardiomyocytes to biomechanical stress,
including pressure or volume overload, reactive oxygen species, cyto-
kines, and circulating neurohormones, which all can activate an intrin-
sic web of interconnected signaling modules within cardiomyocytes.
Many of the stress signaling pathways culminate in the nucleus
with the activation of a set of transcription factors, co-regulators, and
microRNAs (miRNAs, miRs) [3,4], leading to alterations in cardiac
gene expression. The molecular changes observed during the process
of pathological hypertrophy resemble those observed during fetal cardi-
ac development, and therefore cardiac hypertrophy is often described
as being accompanied by the reactivation of a “fetal gene program”
[5–7]. Although elements of this programmight be salutary adaptations
to stress, it has become increasingly clear that the aberrant expression
of fetal genes involved in contractility, calciumhandling, andmyocardi-
al energetics leads to maladaptive changes in cardiac function.
Activation of the “fetal gene program” is believed to play a causativeure pathogenesis and emerging
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ights reserved.role in adverse cardiac remodeling and the pathogenesis of heart failure,
both in humans and in mouse models [8]. Interestingly, upon treatment
of heart failure patients, improvement of ventricular function is often
accompanied with decreased expression of cardiac fetal genes in patients
before and after treatment with beta-blockers [9] and before and after
mechanical unloading with ventricular assist devices [10–12]. Although
mechanical unloading in combination with current pharmacotherapies
has shown effectiveness in prolonging survival of heart failure patients,
the prognosis of affected individuals remains poor. More insight in the
molecular mechanisms underlying the pathogenesis of this disease is
still a prerequisite to design pharmacotherapeutic strategies that may
directly counter the less salutary aspects of the “fetal gene programs”.
Additionally, molecular markers that track the fetal gene program could
serve as useful clinical biomarkers of heart failure progression. Indeed,
circulating NT-proBNP, derived from activation of the human NPPB
gene, has already become a standard biomarker in this area [13]. Here,
we will provide an overview of the mechanistic link between gene regu-
lation in the developing heart and gene regulatory paradigms in the adult
failing heart at the transcriptional, epigenetic and posttranscriptional
level as illustrated in Fig. 1.2. Transcriptional regulation of the fetal gene program
Transcription factors have been demonstrated to play an important
role in embryonic development of the heart. In humans, mutations of
several transcription factors have been associated with a variety of con-
genital heart diseases including atrial septal defect, ventricular septal
defect, tricuspid valve abnormalities and atrioventricular block
(Table 1). Although NKX2-5, and GATA4 are among the most studied
cardiac transcription factors implicated in patients with congenital
heart disease (CHD), the transcriptional regulators described in the
Fig. 1. Simpliﬁed overview of the gene regulatory mechanisms underlying re-expression of fetal gene programs in the adult myocardium. Epigenetic regulators inﬂuence chromatin
condensation surrounding fetal genes, including the methylation status of chromosomal DNA and methylation, acetylation and phosphorylation status of histones. In addition, several
transcriptional regulators drive direct activation of fetal gene programs. In turn, some of the transcription factors are regulated by histone acetyl transferases (HATs) and histone
deacetylases (HDACs). Finally, post-transcriptional mechanisms by speciﬁc miRNA species have been demonstrated to directly inﬂuence fetal gene programs and cardiac hypertrophy.
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remodeling of the adult failing heart.
2.1. Nuclear factor of activated T-cells (NFAT)
The calcineurin-regulatedNFAT transcription factor family consists of
four members, NFATc1–c4. Upon dephosphorylation by calcineurin, the
NFAT transcription factor members translocate to the nucleus and bind
a consensus site consisting of (A/T)GGAAA [14]. During cardiogenesis,
calcineurin-NFATc1 signaling is expressed in the murine endocardium
and second heart ﬁeld and plays a major role in valve elongation and
semilunar valve development [15]. Using PCR ampliﬁcation and DNA se-
quencing is has been shown that differential duplication of an intronic
region in the NFATc1 gene is associated with ventricular septal defects
(Table 1) [16].
In the postnatalmyocardium, NFAT is known to regulate the expres-
sion of “fetal genes”, including brain natriuretic peptide (BNP, Nppb),
the cardiac metabolic gene adenylosuccinate synthetase 1 (Adss1) and
CnAβ (Ppp3cb),which are direct transcriptional targets of NFAT, activat-
ed in synergy with GATA4 [17,18]. Also in cultured cardiomyocytes,
upon calcineurin or agonist stimulation, dominant negative NFAT
reduced ANF (ANF, Nppa) expression [19,20]. Furthermore, inhibition
of the transient receptor potential cation channel TRPC6 reduces
AngII-induced hypertrophy and NFAT activity in cardiomyocytes [21].
In mice overexpressing TRPC6 in the heart, hypertrophic remodeling
was induced, accompanied by increased activation of calcineurin/
NFAT signaling [22]. In human heart failure, TRPC6 was enhanced, indi-
cating the importance of these channels during cardiac pathology.Table 1
Mutations in cardiac transcription factors associated with congenital heart disease.
Transcription factor Associated CHD phenotype References
NFATC1 VSD [16]
MEF2A CAD [35]
GATA4 ASD, AVSD, VSD, PS, AR, VPS, PDA, TOF, AF [49–65]
GATA6 PTA, TOF, ASD [70–72]
NKX2-5 ASD,VSD, AVSD, TOF, SVAS, LVNC, PA, PS,
PDA, MV anomalies, conduction defects,
DORV, PAPVR, TAPVR, heterotaxy, TGA
[64,65,78–91]
NKX2-6 PTA [92]
Abbreviations used: AF, atrialﬁbrillation; AR, aortic regurgitation; ASD, atrial septal defect;
AVSD, atrioventricular septal defect; CAD: coronary artery disease; DORV, double outlet
right ventricle; LVNC, left ventricular noncompaction; MV, mitral valve; PA, pulmonary
atresia; PAPVR, partial anomalous pulmonary venous return; PDA, patent ductus
arteriosus; PS, pulmonary stenosis; PTA, persistent truncus arteriosus; SVAS, supravalvar
aortic stenosis; TAPVR, total anomalous venous return; TGA, transposition of the great
arteries; TOF, tetralogy of Fallot; VSD, ventricular septal defect.Interestingly, in the TRPC6 promoter region, two functional NFAT bind-
ing sites have been reported [22]. Thus, TRPC6 induces calcineurin/
NFAT signaling, which in turn again regulates expression of TRPC6,
thereby creating a positive feedback mechanism. Another NFAT target
gene isRcan1.4, harboring 15 consensusNFATbinding sites in thenucle-
otide sequence upstream of exon 4 [23]. Depending on its phosphoryla-
tion status and expression levels, Rcan1 can both enhance and decrease
calcineurin/NFAT activity [24–27].
In addition, NFAT also has been shown to regulate expression of
miRNAs. For example, it has been reported that miR-199b is a direct
downstream target of the NFATc2 isoform in the heart [28]. MiR-199b
targets Dyrk1a, a nuclear kinase involved in NFAT phosphorylation.
Likewise, miR-23 is a direct NFATc3 target and is induced upon cardiac
hypertrophy [29]. ThismiRNAwas shown to targetMUscle speciﬁc Ring
Finger protein (MuRF1) and Foxo3a, both of which are independently
involved in hypertrophic remodeling. Furthermore, deletion of miR-23
attenuated cardiac hypertrophy [30,31].
2.2. Myocyte enhancer factor 2 (MEF2)
TheMEF2 family of transcription factors is encoded by the four genes
MEF2A–D. MEF2 proteins bind the DNA sequence CAT(A/T)4TA(G/A)
as homo- or heterodimers. Although MEF2A through MEF2D are
expressed in many types of cells, their speciﬁc functions are assigned
to transcriptional regulation in the immune system, neurons, and striat-
ed muscle. At E7.5, MEF2B and MEF2C are initially expressed in the
cardiac mesoderm, followed a day later by expression of MEF2A and
MEF2D. MEF2C transcripts are detected in the somites at E8.5, concom-
itant with the onset of myocyte differentiation in the myotome.
Targeted disruption of MEF2C has been shown to evoke death at E9.5
due to arrested cardiac looping and right ventricular formation during
murine embryogenesis [32]. Also, systematic mutational screening of
the entire MEF2A gene identiﬁed a 21-base pair deletion in exon 11 in
patients with an autosomal dominant form of coronary artery disease,
adCAD1 [33].
In the postnatal heart, MEF2 genes play a role in hypertrophic re-
modeling. TheMEF2-binding A/T-richDNA sequences have been identi-
ﬁed within the promoter regions of a number of fetal and cardiac genes
involved in contractility including muscle creatine kinase gene (Ckm),
α-myosin heavy chain (Myh6), myosin light chain 1/3 (Myl1), myosin
light chain 2v (Myl2), skeletal α-actin (Acta1), sarcoplasmic reticulum
Ca2+-ATPase (Atp2a2), cardiac troponin T (Tnnt2), cardiac troponin C
(Tnnc1), cardiac troponin I (Tnni3), desmin (Des), and dystrophin
(Dmd). Accordingly, forced expression of MEF2A, MEF2C and MEF2D
in transgenic mice proved sufﬁcient to drive intolerance to pressure
overload, ventricular chamber dilation and contractile dysfunction
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showed attenuated postnatal myocardial growth in calcineurin-
induced hypertrophy. Furthermore, it has been shown that the deple-
tion of MEF2C by siRNA attenuates both the hypertrophic cardiac
growth and the upregulation of Nppa in response to pressure overload
[37]. Also, in dominant-negative MEF2D mice, no cardiac hypertrophy,
ﬁbrosis or fetal gene activation was observed in response to pressure
overload. Together, these data demonstrate a role for MEF2 transcrip-
tion factors in both cardiac development and pathological hypertrophy.2.3. GATA-binding proteins
GATA transcription factors are characterized by the conserved dou-
ble zinc ﬁngers that are required for binding to the speciﬁc consensus
DNA sequence (A/T)GATA(A/G). There are 6 GATA transcription factors
known, among which GATA4, GATA5 and GATA6 are expressed in the
heart with an overlapping pattern [38–40], and interact with each
other in outﬂow tract development and cardiac morphogenesis in the
developing embryo. GATA4 is highly expressed in cardiac myocytes,
endocardial and epicardial cells of the heart, and is crucial for normal
cardiac development, as mouse embryos lacking GATA4 die by E8.5
with defective heart tube morphogenesis from a lack of ventral folding
[41,42]. Inactivation of GATA4 in endothelial cells causes failure of endo-
cardial cushion formation and remodeling,which leads to embryonic le-
thality by E12.5 [43]. Select deletion of GATA4 in cardiomyocytes results
in myocardial thinning and hypoplastic endocardial cushions during
embryonal development [44]. Functional analysis of the cis-regulatory
elements has revealed that by binding to promotor sequences, GATA4
directly regulates expression of several cardiac-speciﬁc genes, such as
Myh6,Myl1, Tnnc1, Tnni3, Nppa, Nppb, cardiac-restricted ankyrin repeat
protein (Ankrd1), cardiac sodium–calcium exchanger (Slc8a1), cardiac
M2 muscarinic acetylcholine receptor (Chrm2), A1 adenosine receptor
(Adora1), and carnitine palmitoyl transferase I β (Cpt1b) [44]. Patients
with deletions in the GATA4 locus display several severe forms of
congenital heart disease, including atrioventricular septal defects, aortic
regurgitation, outﬂow tract alignment defects, dextrocardia, tetralogy of
Fallot, patent ductus arteriosus and pulmonary stenosis [45–58]. Link-
age analyses demonstrated an association between GATA4 mutations
and multiple cardiac defects including, atrial septal defects and ventric-
ular septal defects [59–61].
In the adult heart, cardiac-speciﬁc overexpression of GATA4 induces
hypertrophic remodeling [62]. Furthermore, expression of a dominant
negative GATA-engrailed fusion protein or antisense GATA4 mRNA
each blocked GATA4-directed features of cardiac hypertrophy induced
byphenylephrine and endothelin-1 in culture [62]. GATA4 is also direct-
ly phosphorylated by extracellular signal-regulated kinase 1/2 (ERK1/2)
and p38 mitogen-activated protein kinase (p38 MAPK) as a means of
enhancing hypertrophic gene expression. Knock-in mice in which a
known MAPK phosphorylation site at serine 105 (S105) in GATA4 that
augments activity was mutated to alanine (homozygous GATA4-
S105A mutant mice), showed a compromised stress response of the
myocardium [63]. Cardiac hypertrophy in response to phenylephrine
agonist infusion for 2 weeks was largely blunted in GATA4-S105A
mice, as was the hypertrophic response to pressure overload at 1 and
2 weeks of applied stimulation. Also in these GATA4-S105A mice,
down-regulation of fetal genes such as Nppb, Nppa and Myh7 was
observed [63]. Furthermore, deletion of GATA4 speciﬁcally in cardiac
myocytes by using a Cre-loxP approach resulted in spontaneous heart
failure with aging, and younger adult targeted mice subjected to stress
stimulation failed to mount an effective hypertrophic response. Gene
expression proﬁling revealed up-regulation of the fetal genes Nppb,
Nppa andMyh7 as well as genes associated with apoptosis and ﬁbrosis
[64,65]. These studies suggest that GATA4 is a crucial regulator of
adaptive cardiac growth in response to pathologic and even physiologic
stress stimulation by activating fetal genes.GATA6 also participates in postnatal heart disease and GATA6muta-
tions have been shown to be associatedwith atrial septal defects, tetral-
ogy of Fallot and persistent truncus arteriosus [66–68]. GATA6-deleted
mice develop less cardiac hypertrophy following angiotensin II/
phenylephrine infusion,while GATA6 overexpression induces hypertro-
phy with aging and are predisposed to greater hypertrophy with
pressure overload stimulation [69]. Also, GATA6−/− hearts showed a
greater induction of mRNA for fetal genes associated with heart failure
and stress stimulation. Combinatorial deletion of GATA4 and GATA6
from the adult heart resulted in dilated cardiomyopathy and lethality
by 16 weeks of age [69]. GATA5 is able to interact with GATA4 and
GATA6, but whether GATA6 alone or in combination with GATA4 or
GATA5 regulates the hypertrophic response in the adult heart is not
known yet and requires additional research [70].2.4. Cardiac homeobox transcription factor Csx/NKX2-5
The ofﬁcial name of NKX2-5 is NK-2 transcription factor related,
locus 5 (also known as Csx). This name refers to the grouping of
homeodomain-containing proteins of 20 different classes, one of
which is the NK-2 class. Within the NK-2 genes expressed in verte-
brates, a subset, referred to as the “cardiac group”, includes NKX2-3,
NKX2-5, NKX2-6, NKX2-7, NKX-8, and NKX2-10. The homeodomain of
NKX2-5 has a helix-turn-helix motif that binds to the DNA consensus
sites 5′-TNAAGTG-3′ and 5′-TTAATT-3′. Amongst the NK-2 genes,
NKX2-5 plays a crucial role during embryonic heart development.
NKX2-5 is expressed in the heart throughout life and it is the earliest
known marker for myocardial progenitor cells. During embryogenesis
in the mouse heart, NKX2-5 transcripts commit to the cardiac lineage
and are ﬁrst detected at the end of gastrulation, where they are highly
expressed in myocardial progenitor cells [71–73]. Although NKX2-5
knock-out mice start to form a heart and express a variety of cardiac
speciﬁc genes, they fail to progress much beyond the linear heart tube
stage. The heart of NKX2-5 mutant mouse embryos does not loop, nor
develop endocardial cushions nor trabeculae [73]. Mice carrying
NKX2-5mutations have phenotypes that include compromised physiol-
ogy, morphology, and function of the heart. Also in humans, mutations
in NKX2-5 have been associated with a variety of congenital heart dis-
eases including atrial septal defect, ventricular septal defect, tricuspid
valve abnormalities and atrioventricular block (Table 1) [60,61,74–87].
Analysis of NKX2-5 mutations in patients with congenital heart disease
frequently show reduced DNA binding and transcriptional activation by
NKX2-5 [79,87].
So far, a great deal is known about the role of NKX2-5 in heart
development, but less is known about the other cardiac Nk-2 pro-
teins. For example, although persistent truncus arteriosus is associ-
ated with a homeodomain mutation of NKX2.6 (Table 1) [88], mice
with a null mutation for NKX2-6 do not have a cardiac phenotype
and it has been postulated that the loss of NKX2-6 was compensated
by an increase in NKX2-5 expression [89]. However, it is still unclear
which, if any, combination of cardiac NK-2 genes can contribute to
heart development.
In adult NKX2-5 null mice, the expression of the fetal genes Nppa
andNppb, but alsoMyl2,Mef2c,Hand1,Msx2, and Irx4were signiﬁcantly
perturbed. A ventricular-restricted knock-out of NKX2-5 using a
MLC2v-Cre deleter strain resulted in aberrant expression of atrial and
conduction system genes in adult ventricular myocardium [90,91]. Al-
though NKX2-5 transgenic mice only increase fetal gene expression in
the heart without cardiac hypertrophic remodeling, NKX2-5 interacts
with other factors that are known to regulate hypertrophy such as the
transcription factors GATA4 and serum response factor (SRF), or the
co-factor calmodulin-binding transactivator (Camta1) [92,93]. Taken
together, these reports support the contention that NKX2-5 plays a
critical role in fetal gene reactivation and cardiac hypertrophy in the
adult heart.
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The SMAD family can be divided into three different functional
classes: the receptor-activated R-SMADs (SMAD1, -2, -3, -5, and -8), the
co-mediator Co-SMADs (SMAD4), and the inhibitory I-SMADs (SMAD6
and -7). R-SMADs are predominantly localized at the cytoplasm,
Co-SMADs are distributed in the cytoplasm and the nucleus, and
I-SMADs are foundmostly in the nucleus [94]. SMADs bind to the consen-
sus sequence 5′-GTCT-3′with low afﬁnity. Therefore, the binding of only
SMADs to this sequence is not thought to be sufﬁcient to signiﬁcantly
affect promoter activity of a target gene. Consequently, recruitment of
SMADs to a DNA binding site is regulated by cooperationwith other tran-
scription factors, which creates a large spectrum of sequence-speciﬁc
binding patterns.
During cardiac development, SMADs regulate endocardial cushion
formation, valve morphogenesis, and outﬂow tract formation down-
stream of TGF-β and bonemorphogenic protein (BMP) [95,96]. The pri-
mary function of BMP is in heart development. Treatment of embryonic
cells with BMP induces differentiation into cardiomyocytes via SMAD1/
4 signaling. Overexpression of SMAD6, an inhibitory SMAD protein that
speciﬁcally inhibits BMP-mediated SMAD activation, prevents myocyte
differentiation [97], and SMAD6knock-outmice have several cardiovas-
cular abnormalities [98]. Finally, it was observed that SMAD proteins to-
getherwithGATA4 regulate expression of theNKX2-5 cardiac enhancer,
which implicates a role for SMADs regulating the cardiac cell lineage
[99].
In the adult heart, SMADs are critically involved in multiple aspects
of pathophysiology, including the regulation of cardiac ﬁbrosis, apopto-
sis and hypertrophic remodeling. In response to cardiomyopathy and
myocardial infarction, increased expression of (transforming growth
factor-β) TGF-β and Smad2, 3, and 4 in the heart has been observed
[100]. In cardiac ﬁbroblasts, phosphorylation of SMAD2 was associated
with ﬁbrosis and scar formation [101]. By overexpressing SMAD7
(I-SMAD) inﬁbroblasts, collagen synthesis could be inhibited [102]. Fur-
thermore, decreased levels of TGF-β and SMAD2 activity is associated
with decreased ﬁbrosis after angiotensin II receptor stimulation [103].
Also, by using TGF-β1 heterozygous mice, both myocardial infarction-
mediated ﬁbrosis and aging associated ﬁbrosis were diminished [104].
In addition to the ﬁbrotic effects associated with TGF-β/SMAD signaling
in the heart, SMAD1 mediates the anti-apoptotic action of BMP-2 in
neonatal cardiomyocytes [105]. This anti-apoptotic effect of BMP-2/
SMAD1 signaling could be repressed by SMAD6 [106]. Targeted disrup-
tion of SMAD4 leads to an increased heart weight/body weight ratios
compared with their littermates and increased expression of Nppa,
Nppb and Myh7. Moreover, cardiac-speciﬁc SMAD4-deﬁcient mice
display increased left ventricular and intraventricular septal wall thick-
nesses compared to wild type mice [107]. In line, the TGF-β family
member growth-differentiation factor 15 (Gdf15) was demonstrated
to function as an anti-hypertrophic regulator [108]. TGF-β1 itself has
been shown to have pro-hypertrophic effects in the adult heart.
Deletion of TGF-β1 in themouse reduced angiotensin II-induced hyper-
trophy and TGF-β1 overexpression mice develop cardiac hypertrophy,
supporting a prohypertrophic role for TGF-β1, likely by signaling
through MAPK signaling, including TGF-β-activated kinase 1 (TAK1).
In line, TAK1 overexpression mice have been shown to develop cardiac
hypertrophy and induction of fetal gene programs [109].
2.6. Serum response factor (SRF)
SRF belongs to an ancient DNA-binding protein family, which shares
a highly conserved DNA-binding and dimerization domain termed the
MADS box (similar to the MEF2 transcription factor family described
earlier). SRF binds to the SRF-binding consensus element known as
the CArG box and is essential for cardiac differentiation and maturation
[110–114]. A CArG box consists of the sequence CC(AT)6GG and found
primarily in promoters of genes involved in cell growth, migration,differentiation, cytoskeleton organization and energy metabolism. In
the developing heart, cardiac-speciﬁc deletion of SRF disrupts proper
heart development and results in severe defects in the contractile
apparatus of cardiomyocytes, which leads to death in the embryonic
gastrulation stage [112,114]. Also, SRF deletion in mouse embryos re-
sults in impaired gastrulation and lethality beforemesoderm formation,
which suggests an essential role for SRF in mesoderm formation during
mouse embryogenesis [110].
In the postnatal heart, cardiac-speciﬁc overexpression of the SRF gene
with a double mutation (dmSRF) attenuated the total SRF binding activ-
ity and resulted in dilated cardiomyopathy and death within the
ﬁrst 12 days after birth [111]. In line with this, cardiac-speciﬁc and
tamoxifen-inducible disruption of SRF inmice results in decreased levels
of proteins involved in sarcomeric function (force generation and trans-
mission), ﬁbrotic development, and changes in the cytoarchitecture of
cardiomyocytes without hypertrophic compensation [115]. Further-
more, loss of SRF in the postnatal heart leads to increased expression of
the fetal genes Nppa, Nppb and Myh7 and a decreased expression of
sarcoplasmic reticulum Ca2+-ATPase 2a (SERCA2) and the cardiac
sodium–calcium exchanger (NCX1) [116]. Additionally, mRNA array
analysis of SRF deletion in cardiomyocytes resulted in downregulation
of genes encoding sarcomeric proteins and other cardiac transcription
factors [117]. Due to the cardiac changes upon deletion of SRF, these
mice developed severe dilated cardiomyopathy, which lead to heart
failure and death around 10 weeks after triggering SRF loss [118]. Inter-
estingly, increased expression of insulin-like growth factor, which has
been shown to improve myocardial function in pathological situations
[119,120], was also able to protect the heart against dilated cardiomyop-
athy evoked by SRF deletion [116]. Also in humans it has been suggested
that late alterations of SRF function is associated with cardiomyopathies,
which eventually could lead to heart failure [121,122].
SRF associates with tissue-speciﬁc regulatory cofactors, including
GATA4 and NKX2-5, which independently regulate hypertrophic gene
expression in the adult heart [93]. Furthermore, SRF regulates microRNA
expression levels. Cardiac-speciﬁc overexpression of SRF led to altered
expression of a number of microRNAs, such as a downregulation of
miR-1, miR-133a and upregulation of miR-21, microRNAs known to be
involved in cardiac hypertrophic remodeling. Reduced cardiac SRF
expression levels resulted in an increased expression of miR-1, miR-
133a and a decreased expression of miR-21 [123].
3. Epigenetic control of the fetal gene program
In eukaryotes, packaging of genomic DNA into chromatin is a central
mechanism for gene regulation. The fundamental unit of the chromatin
is the nucleosome, which envelops a histone octamer. To repress gene
expression, nucleosomes interact to create a highly compact structure
that limits access of transcriptional machinery to genomic DNA. During
organ development, but also in the process of hypertrophic remodeling,
epigenetic changes regulate gene activity. These epigenetic modiﬁca-
tions of chromatin include methylation of genomic DNA as well as
acetylation, methylation, and phosphorylation of histone proteins.
3.1. Histone acetyltransferases (HATs)
Acetylation of the amino-terminal histone tails by histone
acetyltransferases (HATs) relaxes nucleosomal structure by weakening
the interaction of the positively charged histone tails with the negative-
ly charged phosphate backbone of the DNA, allowing access of
transcriptional activators and induction of gene expression. In cardiac
muscle, the most extensively studied HATs are p300 and the closely re-
lated coactivator, CREB-binding protein (CBP). P300 relaxes chromatin
structure and promotes gene activation by modifying chromatin and
associated transcription factors. The ﬁrst evidence for a role of HATs in
cardiac muscle was shown by deletion of p300, which perturbed heart
development and cell proliferation. P300 knockout mice died between
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creased expression of β-MHC and α-actinin, and reduced trabeculation
[124]. Furthermore, a gene knock-in approach demonstrated that the
HAT domain of p300 seems to be essential for heart formation [125].
In the adult heart, p300 and CBP play a critical role in cardiac hyper-
trophic remodeling that is dependent on their histone acetyltransferase
activity [126]. In cardiomyocytes, agonist-induced hypertrophy leads to
increased levels of p300 [127]. Furthermore, overexpression of both
p300 and CBP stimulates agonist-induced cardiac hypertrophic growth,
while dominant-negative mutants of p300 block agonist-mediated
cardiac hypertrophy [126,128].
Besides acetylation of histone tails, p300 also affects the activity of
hypertrophy-responsive transcription factors, such as GATA4, SRF, and
MEF2 [129–132]. Together, these studies show a role for p300 and
CBP in stimulating activity of fetal genes during the process of cardiac
hypertrophy.
3.2. Histone deacetylases (HDACs)
Histone deacetylases (HDACs) catalyze the removal of acetyl groups
from conserved lysine residues in histone tails, thereby inducing chro-
matin condensation and transcriptional repression. HDACs are classiﬁed
into four subfamilies (classes I, IIa, IIb, and IV). Class I HDACs consist of
HDAC1, 2, 3, and 8 proteins, which are localized predominantly in the
cell nucleus, and display high enzymatic activity toward histone sub-
strates. Most class I HDACs are part of multiprotein nuclear complexes
crucial for transcriptional repression, and have important functional
roles in regulating cellular proliferation and survival (reviewed in
[133]). Class II HDACs are further subdivided into class IIa (HDAC4, 5,
7, and 9) and class IIb (HDAC6 and 10) [134]. Class IIa HDACs function
more as signal transducers that shuttle between the cytoplasm and
the nucleus and have only weak enzymatic activity. Shuttling of class
IIa HDACs is dependent on phosphorylation of two serine-containing
motifs found exclusively in the amino-terminal extensions of HDAC4,
HDAC5, HDAC7, and HDAC9. In higher eukaryotes 14-3-3 proteins
have also been shown to be involved in nucleo-cytoplasmic shuttling
of HDAC5, where phosphorylated HDAC5 binds to 14-3-3 and is
transported out of the nucleus [135,136]. Class IIa HDACs can also regu-
late gene repression by interacting with class I HDACs and other tran-
scriptional repressors such as nuclear receptor corepressor (N-CoR),
silencing mediator of RA and thyroid hormone receptors (SMRT),
heterochromatin protein 1, and C-terminal-binding protein. Class III
HDACs, or sirtuins, require NAD + for deacetylation and regulate
transcriptional repression. Sirtuins have no sequence similarity to
class I and II HDACs.
3.2.1. Class I HDACs
HDACI plays a critical role during embryonic development. HDAC1
knock-out mice die before E10.5 secondary to severe proliferation
defects, indicated by elevated levels of the cyclin-dependent kinase
inhibitors p21(WAF1/CIP1) and p27(KIP1) [137,138]. A recent study
also implicates HDAC2 in cardiac hypertrophy. Cardiac overexpression
of a heart-enriched nuclear protein, homeodomain-only protein
(HOP), induces hypertrophic remodeling and subsequent heart failure.
By recruiting HDAC2, HOP is able to repress SRF. In the same study, it
was reported that HDAC inhibitors could block HOP-induced cardiac
growth, suggesting HOP as a potential target of HDACs during cardiac
hypertrophy [139]. Also cardiac-speciﬁc HDAC3 KO mice showed
massive cardiac hypertrophy accompanied by up-regulation of genes
involved in fatty acid uptake and oxidation [140]. However, deletion
of HDAC3 by a Cre deleter strain under control of the Muscle creatine
kinase (Mck) promoter, did not lead to such signiﬁcantmyocardial dys-
function on normal chow, but develop severe cardiomyopathy leading
to deathwhen animalswere fed a high fat diet [141]. The differences be-
tween the two mouse models likely relates to the time point of HDAC3
deletion. Using the MHC-Cre deleter strain, HDAC is removed duringmid-gestation, while the MCK-Cre deleter strain is active in heart and
skeletal muscle at postnatal time points. The more severe phenotype
produced by earlier deletion of HDAC3 suggests that HDAC3 is also
important during cardiac development. The cardiac changes observed
in both mouse models seem to be due to increased activity of PPARα.
Also, HDAC3 can bind and deacetylate MEF2 and thereby lead to
transcriptional repression of MEF2 [142].
3.2.2. Class IIa HDACs
A decade ago, it has become clear that class IIa HDACs play a prom-
inent role as signal-responsive suppressors during the development of
cardiac hypertrophy. Adenoviral overexpression of constitutive active
mutants of HDAC4, HDAC5, and HDAC9 has been shown to prevent
agonist-induced cardiomyocyte hypertrophy [143]. At early age, mice
lacking either HDAC5 or HDAC9 are viable and show no evidence of
cardiac abnormalities. Only when HDAC5/9 null mice reach the age of
6 months, they develop spontaneous cardiac hypertrophy. However,
the majority of HDAC5/9 double-mutant mice die during late embryo-
genesis with thin-walled myocardium and ventricular-septal defects,
suggesting that these HDACs are required for proper heart develop-
ment. In the adult heart, either single HDAC5- or HDAC9-deﬁciency
leads to the development of hypertrophy [144,145]. In contrast, in re-
sponse to chronic β-adrenergic stimulation with isoproterenol, which
is known to induce hypertrophy by acting through the cAMP-signaling
pathway, these mice seem to have a normal cardiac morphology. Such
ﬁndings indicate that both HDAC5 and HDAC9 function as antagonists
of hypertrophic remodeling, speciﬁcally dependent on intracellular
calcium signaling.
Furthermore, class IIa HDACs have the potential to repress
hypertrophy-responsive genes recruited via MEF2. Class IIa HDACs are
able to bind to MEF2 via an18-amino-acid motif present only in these
HDACs. In HDAC knockout mice, cardiac hypertrophy is associated
with enhanced activation of MEF2. A complex between class IIa
HDACs and MEF2 will be formed, resulting in repression of genes har-
boring MEF2-binding sites. As discussed earlier, p300 has also been
shown to associate with MEF2. Thus, both class IaI HDACs and HATs
can bind MEF2, which then acts as platform to respond to positive or
negative transcriptional signals by exchanging HATs and class IIa
HDACs. Not only do HATs and class IIa HDACs compete for association
with MEF2, also MEF2 and calmodulin (CaM) compete with each
other to associate with class IIa HDACs. Upon binding of Ca2+ to CaM,
CaM is able to interact with class IIa HDACs, which lead to HDAC phos-
phorylation and displacement ofMEF2 accompanied by derepression of
MEF2 target genes [146]. In addition, CaM is also able to bind to Cabin1,
a transcriptional repressor of MEF2. Upon increased intracellular calci-
um levels, CaM competes with MEF2 for binding to Cabin1, resulting
in the dissociation ofMEF2 from its repressor Cabin1 and, consequently,
in MEF2 activation [147]. Additionally, class IIa HDACs are able to re-
press other transcription factors either directly or indirectly, including
SRF, GATA, NFAT, and myocardin, all of which have a known role in hy-
pertrophic remodeling [148–152].
3.2.3. Class III HDACs
Class III HDACs (sirtuins) function in awide array of cellular process-
es, including gene silencing, longevity, and DNA damage repair. There
are several sirtuin isoforms distributed in different subcellular compart-
ments, including the nucleus (SIRT1, -2, -6, and -7), cytoplasm (SIRT1
and -2), and mitochondria (SIRT3, -4, and -5) [153]. SIRT1 has been
shown to deacetylate many transcription factors, including p53, and
Forkhead box O (FoxO) transcription factors. In the adult heart, SIRT1
expression levels are increased by stress, such as pressure overload
and nutrient starvation [154,155]. Another member of the sirtuin fami-
ly, SIR2α, was reported in nuclei of cardiac myocytes. Inhibition of
SIR2α by the inhibitors nicotinamide or sirtinol induced myocyte
apoptosis. In line with this, also expression of dominant-negative
SIR2α leads to increased levels of apoptosis [156]. Furthermore,
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which was associated with an increased size of cardiomyocytes.
Furthermore, SIR2α expression levels were elevated in hearts from
dogswith heart failure induced by rapid pacing superimposed on stable,
severe hypertrophy. Thus, increased SIR2α expression during heart
failure may play a cardioprotective role in vivo.3.3. Histone methylation
Histone methylation can lead to both facilitation and repression of
gene expression. For instance, methylation of H3K4 is associated with
active genes, while dimethylation or trimethylation of H3K9 primarily
occurs during gene repression. In the healthy heart, the methylation
status is balanced by activities of histone methyltransferases (e.g. G9a
and SUV39H1) and histone demethylases (e.g. JMJD1 and JMJD2)
[157]. In human failing hearts, differential methylation patterns of
H3K4 and H3K9 have been observed in various gene clusters.3.3.1. Jumonji
Jumonji (Jmj) contains the conserved Jumonji C (JmjC) domain and
belongs to a histone demethylase family. Jmj has a methyltransferase
rather than a demethylase activity and it recruits G9a and GLP
methyltransferases to methylate H3K9 and repress the cyclin D1 pro-
moter [158]. Jmj KOmice have been shown to suffer from various cardi-
ac defects. One study showed that Jmj KO mice are born (p = 0) with
ventricular septal defects, ventricular noncompaction, and double outlet
of the right ventricle [159], while another study demonstrated that Jmj
KO embryos (with a C3H/He background), die between E11.5 and E12.5
and display abnormalities in the right heart and hyperplasia of the
trabecular myocardium, resulting in obstruction of the ventricle [160].
In vitro experiments using neonatal cardiomyocytes demonstrate
that Jmj associates with GATA4 and NKX2-5 to repress Nppa expres-
sion [161], and Jmj has also been demonstrated to repressMyh6 expres-
sion by inhibiting MEF2A activity [162].
In human failing hearts, an upregulation of JMJC domain-containing
demethylases has been observed [157]. Expression of JMJD1A, JMJD2A,
and JMJD2B was 2-fold increased in failing versus nonfailing myocardi-
um. In these human failing hearts, upregulation of JMJD1A correlated
positively with increased Nppa and Nppb expression and inversely
with H3K9me2 in the promoter region of Nppa. By performing ChIP as-
says, this study demonstrated that both JMJD1A and JMJD2A are bound
to the promoter regions of Nppa in non-failing and failing myocardium
of patients with ischemic or dilated cardiomyopathy [157].3.3.2. HDAC4 and H3K9 demethylation
In response to G-protein coupled receptor (GPCR) activation, Ca2+/
calmodulin-dependent kinase II (CaMKII), protein kinase D, and
reactive oxygen species, export of HDAC4, HDAC5, and HDAC9 from
the nucleus to the cytosol is mediated. HDAC4 is able to repress gene
transcription by interactingwithMEF2, and at least part of its repressive
function is related to keeping the respective promoter region in a
deacetylated state. In human failing hearts, histone acetylation was
not required for Nppa and Nppb gene activation, although pronounced
nuclear export of HDAC4 was observed [157]. In contrast, H3K9
demethylation was closely associated with reactivation of fetal genes
and nuclear export of HDAC4. Experiments in genetically modiﬁed
mice revealed that nuclear HDAC4 export was required for H3K9 de-
methylation, HP1 dissociation, and Nppa gene activation in response
to increased hemodynamic load [157]. In that study, protein–protein
interaction of HDAC4 with the histone methyltransferase SUV39H1
was disrupted upon nuclear export of HDAC4 in response to targeted
phosphorylation by CaMKIIδB, which might represent a potential
underlying mechanism.4. MicroRNA regulation of the fetal gene program
The discovery of the regulatory role of microRNAs (miRNAs, miRs)
has added a new layer of complexity to our understanding of the embry-
onic development of the heart. Furthermore, recent studies established
essential roles for miRNAs in cardiac hypertrophy and heart failure.
miRNAs are 18–24 nucleotide single-stranded RNAs, encoded by the
genome and suppress gene expression by translational repression. The
importance of posttranscriptional regulation by miRNAs for embryonic
developmentwas underscored by generating loss of functionmutations
of enzymes essential for miRNA biogenesis such as Dicer, Drosha, Ago2,
and DGCR8 [163–166]. Deletion of Dicer using Cre recombinase under
control of the endogenous NKX2-5 regulatory region leads to defects
in the ventricular myocardium, cardiac outﬂow tract morphogenesis
and chamber septation, and results in pericardial edema and embryonic
death at E12.5 in the mouse [167]. Also, in the adult heart, loss of Dicer
induced pathological cardiac hypertrophy, accompanied by myoﬁber
disarray, ventricular ﬁbrosis, and strong induction of fetal gene
transcripts [168]. DGCR8 inactivation in neural crest cells (using a
Wnt1-Cre) revealed major cardiovascular defects at E18.5, including
persistent truncus arteriosus, interrupted aortic arch, cervical aortic
arch and aberrant origin of the right subclavian artery [169]. Together,
these studies show that miRNA biogenesis is essential for normal cardi-
ac development and survival. Although limited information is available
about speciﬁc miRNAs that are involved in fetal gene regulation both
during embryonic development and in heart failure, Thum and
colleagues showed that fetal gene reactivation in human heart failure
is, at least in part, driven by differential miRNA expression patterns
[4]. Other examples are discussed below.
4.1. The miR-1~133 cluster
A subset ofmiRNAs, which are either speciﬁcally or highly expressed
in cardiac and skeletal muscle, termed myomiRs, include miR-1, -133,
-206 and -208 [170]. The miR-1 and miR-133 families are co-
expressed. The miR-1 and miR-133 families are co-expressed. The
miR-1 subfamily consists of two closely related transcripts, miR-1-1
and miR-1-2, and the miR-133 family comprises miR-133a-1, miR-
133a-2 and miR-133b. Both in humans and in mice, miR-1-1 and miR-
133a-2 form a cluster on chromosome 2 and miR-1-2 and miR-133a-1
form another cluster located on chromosome 18 [171].
During early stages of embryonic development, miR-1 and miR-133
are functionally expressed to promote mesoderm induction and
suppress differentiation into the ectodermal or endodermal lineages in
animals such asmice and zebraﬁsh [171,172]. miR-1 promotes differen-
tiation of cardiac progenitors and decreases cell proliferation in mam-
mals and ﬂies [173,174]. In contrast, miR-133 inhibits differentiation
of skeletal myoblasts and maintains them in a proliferative state [171].
Furthermore, while miR-1-1 is initially strongly expressed in the less
proliferative inner curvature of the heart loop and in atria, miR-1-2 is
expressed mainly in the ventricles [175]. This suggests that the miR-1
and miR-133 family are regulated and expressed differentially during
cardiac development.
Overexpression of miR-1 in a transgenic mouse model results in a
phenotype characterized by thin-walled ventricles from premature
differentiation and early withdrawal of cardiomyocytes from the cell
cycle [173,176]. Conversely, miR-1-2 deﬁciency in mice results in 50%
embryonic lethality accompanied by thickened chamber walls from
prolonged hyperplasia and ventricle septal defects. The ventral septal
defects might partially be mediated by the transcription factor heart
and neural crest-derivatives-2 (Hand2), which regulates expansion of
ventricular cardiomyocytes by inhibiting cardiomyocyte progenitor
proliferation [174,177]. Overexpression of miR-133 after injury of a
zebraﬁsh heart resulted in reduced myocardial regeneration, while
impaired expression of miR-133 was responsible for increased
cardiomyocyte proliferation [178]. Along with miR-1, these two
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and dosage of miRs for heart development [175]. Interestingly, several
transcription factors, including SRF, MEF2, GATA4 and NKX2-5, have
been shown to regulate the expression of the bicistronic miRNA
pairs miR-1-1/miR-133a-2 and miR-1-2/miR-133a-1 [171,174]. SRF
enhances the expression of these miRNAs in ventricular and atrial
myocytes [179], whereas MEF2 binds to the intronic enhancer of these
miRs to activate their expression in ventricular myocytes. In addition,
several direct targets of miR-1 have been described in vivo, including
the transcription factor Hand2 and the Notch Delta ligand in Drosophila.
Similarly, Delta-like 1 (Dll-1), a human homolog of the Notch Delta, is
translationally repressed in miR-1 expressing mouse embryonic stem
cells [180].
The upregulation ofmiR-1 to substantial levels in the postnatal heart
suggested an important function in the regulation of postnatal heart
function. Accordingly, it was shown that after aortic constriction-
induced hypertrophy in a mouse model, miR-1 was singularly
downregulated from day 1 until day 7 [181]. Consistently, also in
other genetic models of cardiac hypertrophy, including the calcineurin
and v-aktmurine thymoma viral oncogene homolog 1 (AKT) transgenic
hearts, miR-1 was downregulated [182,183]. Although in mice, a de-
creased expression of miR-1 has been reported, in humans the mea-
surements of miR-1 have been less consistent. Although Ikeda et al.
and Naga Prasad et al. report a reduction in miR-1 in ischemic and
non-ischemic dilated cardiomyopathies [183,184], Matkovich et al.
and Kumarswamy et al. report upregulation of miR-1 in human heart
failure [185,186]. Thus in the failing human heart, measurements of
miR-1 levels have been inconsistent and, accordingly, miR-1 function
and targets in that context are less well explained.
Mechanistically, miR-1 has been shown to negatively regulate CaM,
MEF2A, and GATA4, key components of calcium signaling pathways
and fetal gene activation, which are two events that are necessary for
agonist-induced cardiomyocyte hypertrophy in themouse [183]. Indeed,
another study reported that miR-1 overexpression also suppressed ex-
pression of the fetal gene ANF [181]. Furthermore, overexpression of
miR-1 in cultured neonatalmyocytes partially inhibited phosphorylation
of ribosomal S6 protein and several genes that were related to cardiac
growth, including Ras GTPase-activating protein, cyclin-dependent
kinase 9, ﬁbronectin, and Ras homolog expressed in brain [181].
Overexpression of miR-133 resulted in suppression of protein syn-
thesis and inhibition of hypertrophic growth in PE- or endothelin-1-
treated neonatal mouse cardiac myocytes. miR-133a is also known to
regulate the expression of the transcription factor NFATc4 [187] and
miR-133 overexpression leads to the de-repression of fetal genes, in-
cluding Nppa, Acta1, and Myh7. In line with this, miR-133 deletion,
using a targeted 3′ UTR decoy sequence, resulted in marked cell hyper-
trophy and increased protein synthesis, accompanied by increased fetal
gene expression. Furthermore, treatment of mice with an antagomir
against miR-133 resulted in cardiac hypertrophy and re-activation of
the fetal gene program [182].
4.2. miR-208
The miR-208 family consists of two transcripts; miR-208a and miR-
208b, which are both required for cardiomyocyte-speciﬁc gene expres-
sion, cardiomyocyte hypertrophy, and thyroid hormone sensitivity
[3,188]. Both miRs share a high level of sequence homology but
miR-208a is encoded by an intron of its host gene, Myh6 [189], while
miR-208b, is located within an intron of the gene encoding Myh7
[190]. In mice, Myh7 is expressed in the embryonic heart and Myh6 is
predominantly found at postnatal stages. A similar switch from miR-
208b to miR-208a expression takes place right after birth, demonstrat-
ing a parallel expression of these microRNAs with their host genes.
Therefore, miR-208a could be detected in the heart as early as E13.5
but only at very low levels, while miR-208b is much higher expressed
in the developing heart [188]. Genomic deletion of miR-208a withoutimpairing Myh6 expression leads to ectopic expression of fast skeletal
musclemarkers in the adult heart, demonstrating that miR-208a affects
cardiac differentiation. Interestingly, mice lacking miR-208a fail to in-
crease Myh7 levels under stress and do not develop hypertrophy
[189], while deletion of miR-208b did not alterMyh7 expression [191].
In response to pressure overload by thoracic aortic constriction or
signaling by calcineurin, miR-208a deﬁcient mice were resistant to
hypertrophic remodeling, ﬁbrosis and fetal gene activation. Upon stress,
miR-208a inhibits the thyroid receptor-associated protein THRAP1,
which in turn reduces thyroid receptor signaling, leading to increased
Myh7 expression and impaired cardiac function. Apart from Thrap1,
myostatin and GATA4 levels are also regulated by miR-208a, which
demonstrates the functional role of miR-208a in cardiac hypertrophic
remodeling [188]. In line with this, cardiac-speciﬁc miR-208a over-
expression induces cardiac hypertrophy. In miR-208a transgenic mice
and in mice subjected to pressure overload, cardiac expression of miR-
208b and its host gene,Myh7, are induced during hypertrophic remod-
eling [188]. Similar toMyh6 andMyh7, a thirdmyosin gene,Myh7b, also
contains an intronic miR, miR-499. These three miRNA-gene units are
involved in a complicated network regulating muscle function.4.3. Other microRNAs regulating fetal gene reactivation
MiR-9 has been identiﬁed as an anti-hypertrophic miRNA by virtue
of its ability to decrease myocardin expression, which has been identi-
ﬁed as a NFATC3 target. Furthermore, infecting cardiomyocytes with a
miR-9 adenovirus prevented isoproterenol-mediated upregulation of
Myh7 expression [137]. Also, miR-195 has been shown to be involved
in the re-activation of the fetal gene program during pathological
remodeling. miR-195 expression is increased in cardiac hypertrophy,
and cardiac overexpression of miR-195 resulted in pathological cardiac
growth and heart failure in transgenicmice, whichwas accompanied by
an upregulation of Nppa, Nppb andMyh7 [137].5. Concluding remarks
In the adult failingheart,many fetal genes are re-employed,which in
turn activate processes involved in pathological cardiac remodeling. The
re-activation of “fetal” genes in the postnatal myocardium involves the
combined activation of transcriptional processes, chromatin remodeling
and post-transcriptional regulation. All these factors independently act
on a different level of gene regulation, and together form a highly
interconnected network. Both microRNAs and chromatin remodeling
factors inﬂuence activation of transcription factors, which in their turn
regulate the expression of several microRNA genes. These gene net-
works offer multiple therapeutic entry points to dampen the aberrant
expression of fetal genes and adverse remodeling processes of the
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